These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36248989)

  • 21. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
    Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
    J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study.
    Han Z; Yang F; Zhang Y; Wang J; Ni Q; Zhu H; Zhou X; Gao H; Lu J
    Front Oncol; 2022; 12():1029951. PubMed ID: 36591442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.
    Pinter M; Ulbrich G; Sieghart W; Kölblinger C; Reiberger T; Li S; Ferlitsch A; Müller C; Lammer J; Peck-Radosavljevic M
    Radiology; 2015 Dec; 277(3):903-12. PubMed ID: 26131911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study.
    Huang Z; Wu Z; Zhang L; Yan L; Jiang H; Ai J
    Front Oncol; 2024; 14():1298122. PubMed ID: 38318115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
    Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
    J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world.
    Xie D; Sun Q; Wang X; Zhou J; Fan J; Ren Z; Gao Q
    Ann Transl Med; 2021 Apr; 9(8):652. PubMed ID: 33987350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.
    Huang JT; Zhong BY; Jiang N; Li WC; Zhang S; Yin Y; Yang J; Shen J; Wang WS; Zhu XL
    J Hepatocell Carcinoma; 2022; 9():1217-1228. PubMed ID: 36474670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
    Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
    World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma.
    Zhang Z; Jiao T; Li J; Hu B; Zhang W; Wang Z; Wan T; Wang Y; Lu S
    World J Surg Oncol; 2023 Feb; 21(1):53. PubMed ID: 36803872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A real-world study of tyrosine kinase inhibitors plus anti-PD-1 immunotherapy with or without chemoembolization for hepatocellular carcinoma patients with main portal vein invasion.
    Song Z; Wu DD; Fan WZ; Wu MJ; Miao HF; Du JH; Zhang H; Jiang DR; Zhang YQ
    Abdom Radiol (NY); 2024 Jul; ():. PubMed ID: 38977489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres
    Duan X; Liu J; Han X; Ren J; Li H; Li F; Ju S
    Front Oncol; 2021; 11():793581. PubMed ID: 35127501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and safety of anti-PD-1 monoclonal antibody in advanced hepatocellular carcinoma after TACE combined with TKI therapy].
    Xu ZN; Huang JJ; Zhou J; Huang WS; Guo YJ; Cai MY; Zhou JW; Lin LT; Liang LC; Zhu KS
    Zhonghua Nei Ke Za Zhi; 2021 Jul; 60(7):630-636. PubMed ID: 34619840
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis.
    Qin J; Huang Y; Zhou H; Yi S
    Front Oncol; 2022; 12():807102. PubMed ID: 35463356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
    Megías Vericat JE; García Marcos R; López Briz E; Gómez Muñoz F; Ramos Ruiz J; Martínez Rodrigo JJ; Poveda Andrés JL
    Radiologia; 2015; 57(6):496-504. PubMed ID: 25857250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
    Wen P; Chen SD; Wang JR; Zeng YH
    Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma.
    Chen S; Yu W; Zhang K; Liu W; Chen C
    Hepatol Res; 2021 Apr; 51(4):482-489. PubMed ID: 33462925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of cone-beam computed tomography with automated feeder detection software on the survival outcome of patients with hepatocellular carcinoma during treatment with conventional transarterial chemoembolization.
    Bannangkoon K; Hongsakul K; Tubtawee T
    BMC Gastroenterol; 2021 Nov; 21(1):419. PubMed ID: 34749658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
    Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
    Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world.
    Feng JK; Liu ZH; Fu ZG; Chai ZT; Sun JX; Wang K; Cheng YQ; Zhu HF; Xiang YJ; Zhou LP; Shi J; Guo WX; Zhai J; Cheng SQ
    Front Oncol; 2022; 12():954203. PubMed ID: 36505818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.